Klastersky J, Meunier-Carpentier F, Coppens-Kahan L, Daneau D, Prevost J M
Antimicrob Agents Chemother. 1977 Oct;12(4):503-9. doi: 10.1128/AAC.12.4.503.
A preliminary study was conducted with netilmicin, a new aminoglycoside antibiotic. Its effectiveness was evaluated in vitro against 546 strains of Enterobacteriaceae and Pseudomonas aeruginosa isolated from clinical material. Its effectiveness against gentamicin-susceptible strains was roughly similar to that of gentamicin and other newer aminoglycoside antibiotics. Cross-resistance to netilmicin was found in 9 of 44 gentamicin-resistant strains. A favorable clinical response was observed in 70% of the patients treated with a dose of netilmicin ranging from 4.5 to 7.5 mg/kg. However, the appearance of granular casts was seen in 7 of 10 patients receiving the higher dosage of netilmicin (7.5 mg/kg) and a rise in blood urea nitrogen or serum creatinine levels was observed in 5 of these patients.
对一种新型氨基糖苷类抗生素奈替米星进行了一项初步研究。在体外评估了其对从临床材料中分离出的546株肠杆菌科细菌和铜绿假单胞菌的有效性。其对庆大霉素敏感菌株的有效性与庆大霉素和其他新型氨基糖苷类抗生素大致相似。在44株庆大霉素耐药菌株中有9株发现对奈替米星交叉耐药。在用剂量范围为4.5至7.5mg/kg的奈替米星治疗的患者中，70%观察到良好的临床反应。然而，在接受较高剂量奈替米星（7.5mg/kg）的10名患者中有7名出现颗粒管型，其中5名患者观察到血尿素氮或血清肌酐水平升高。
